Mirabegron: first β3 agonist in treatment of overactive bladder
Journal: International Journal of Basic & Clinical Pharmacology (Vol.1, No. 2)Publication Date: 2012-10-01
Authors : Paramdeep Singh Gill Nipunjot Grewal;
Page : 120-121
Keywords : Overactive bladder; Anticholinergics; β3 agonist;
Abstract
Mirabegron is the first and only β3 agonist approved by US FDA in June 2012 for treatment of Overactive bladder with symptoms of urge incontinence, urgency and urinary frequency. It is the first oral OAB treatment with a distinct mechanism of action since the launch of anticholinergic agents 30 years ago. It causes relaxation of detrusor smooth muscle by its agonist action at β3 receptors leading to increased storage capacity of bladder. It has been studied extensively in more than 10,000 individuals over 10 years. [Int J Basic Clin Pharmacol 2012; 1(2.000): 120-121]
Other Latest Articles
- Small size sampling?
- Pediatrics pharmacovigilance: need of a new sub-unit
- Wound healing and anti-inflammatory activity of extract of Ficus racemosa linn. bark in albino rats
- Feed consumption and weight gaining behavior of zucker fatty (fa/fa) rats with single and in combination treatment of clonidine and metformin
- A prospective, open labeled, comparative study to assess the efficacy of montelukast as add on to β2-agonist and inhaled corticosteroid in patients of moderate persistent asthma
Last modified: 2013-03-02 19:52:54